Eris Lifesciences Ltd · NSE:ERIS
Eris Lifesciences — Q3 and 9M FY26 Earnings Presentation
24 slides from Eris Lifesciences's earnings presentation, Feb 13, 2026
Slide 1: Investor Presentation filing cover letter to exchanges
Date: 13 February 2026 To To BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers Exchange Plaza Dalal Street Bandra Kurla Complex Mumbai – 400001 Bandra (E) Mumbai – 400051 Security Code: 540596 Symbol: ERIS SUBJECT: INVESTOR PRESENTATION Dear Sir/Madam, Pursuant to the re
Slide 2: Investor Presentation Q3 and 9M FY26
INVESTOR PRESENTATION Q3 and 9M FY26 13th Feb 2026 1
Slide 3: Domestic Branded Formulations
• Domestic Branded Formulations • International Business • Consolidated 2
Slide 4: DBF Revenue – Q3 and 9M FY26 Financial Highlights
DBF REVENUE – Q3 AND 9M FY26 FINANCIAL HIGHLIGHTS Strong visibility to deliver an FY26 DBF Revenue growth of 12% with 37% EBIDTA margin Q4 FY26 – expecting to accrue the full impact of price increases DBF REVENUE (Rs. Cr.) DBF EBIDTA (Rs. Cr.) 10% 12% 11% 2,106 781 10% 1,911 11% 695 10% 635 696 230
Slide 5: DBF Revenue Composition – Impact of Non-Core/Tail-End Products
DBF REVENUE COMPOSITION – IMPACT OF “NON-CORE/ TAIL-END” PRODUCTS • We have identified a basket of tail-end brands, primarily within general injectables and select other categories, that exhibit the following characteristics • Lack of alignment with core therapies • Low profits and profitability • L
Slide 6: RHI Cartridges – Tripled Market Share Since Acquisition
RHI CARTRIDGES – TRIPLED MARKET SHARE SINCE ACQUISITION RHI Cartridges – Eris market share by Rx RHI Cartridges – Eris market share by Sales + 1,800 bps 28% + 1,700 bps 25% Our stated objective of 25% 23% market share in 15% Insulins at the time of Biocon 10% 8% acquisition • Achieved in RHI Carts s
Slide 7: Overall Insulins Market – Reaffirming Our Right to Win
OVERALL INSULINS MARKET – REAFFIRMING OUR RIGHT TO WIN Total RHI + Glargine – Eris Market Shares Insulin Analogues Product Market Size + 700 bps 16% Aspart and Aspart Mix Rs. 650+ cr. Our Insulins Strategy 13% Degludec & comb. Rs. 800 cr. 25% market share 9% Lispro Rs. 300+ cr. in our core RHI + Tot
Slide 8: Insulin Manufacturing at Bhopal – On Course Despite Delays
INSULIN MANUFACTURING AT BHOPAL – ON COURSE DESPITE DELAYS Product Segment Status of in-house manufacturing RHI Vials Started in Aug-25; manufactured over 5 million vials since Glargine Vials Initiated in Feb 2026 Process Validation batches in Q4-FY26 Cartridges (RHI + Glargine) Commercial manufactu
Slide 9: DBF – Growth on Track Across Core Therapies Excluding OAD
DBF – GROWTH ON TRACK ACROSS CORE THERAPIES EXCLUDING OAD Eris Growth vs. CVM - OHA Eris Growth vs. CVM – Cardiac Care CVM Eris Core portfolio growth trend since Oct ‘25: CVM Eris 9.7 18.8 16.8 9.6 9.6 16.5 • OAD: Eris portfolio impacted by FDCs 14.1 15.5 15.8 7.1 11.0 10.9 ban for important SKUs –
Slide 10: GLP-1 Update – Launch Readiness and Manufacturing Self-Sufficiency
GLP-1 UPDATE – LAUNCH READINESS AND MANUFACTURING SELF-SUFFICIENCY Exciting Market Opportunity Go-to-Market Readiness ▪ Large and fast-emerging GLP-1 market in India ▪ Strategic partnership in place ▪ Endocrinologists/ Diabetologists continue to ▪ Decks cleared for the final approval of the lead the
Slide 11: Launching Esaxerenone: A Game-Changer in Hypertension Management
LAUNCHING ESAXERENONE: A GAME-CHANGER IN HYPERTENSION MANAGEMENT Developed for India by Eris Lifesciences' own in-house R&D team Esaxerenone is the First to launch in India - showcasing our commitment to Patient Care and R&D strength. Disease-Modifying Therapy Proven Clinical Evidence* A Game-Change
Slide 12: International Business
• Domestic Branded Formulations • International Business • Consolidated 11
Slide 13: International Business – Strong Pipeline Drives 45% Growth in Q3
INTERNATIONAL BUSINESS – STRONG PIPELINE DRIVES 45% GROWTH IN Q3 Q3 Revenue* - Rs. Cr. Q3 EBITDA* - Rs. Cr. 45% 111 46% 76 33 22 Q3 FY25 Q3 FY26 Q3 FY25 Q3 FY26 • Q3 revenue Rs. 111 crore with a 45% yoy growth – strongest quarter yet • Q3 EBIDTA Rs. 33 crore with a 46% yoy growth Source – Unaudited
Slide 14: International Business – YTD Growth 11% and On Track as Guided
INTERNATIONAL BUSINESS – YTD GROWTH 11% AND ON TRACK AS GUIDED 9M Revenue* - Rs. Cr. 9M EBITDA* - Rs. Cr. 11% 10% 81 259 233 74 9M FY25 9M FY26 9M FY25 9M FY26 • 9M revenue Rs. 259 crore with a 11% yoy growth • 9M EBIDTA Rs. 81 crore with a 10% yoy growth • Q3 EBIDTA margin at 30% and 9M EBIDTA marg
Slide 15: Significant Visibility on FY27 Being a Breakout Year
SIGNIFICANT VISIBLITY ON FY27 BEING A BREAKOUT YEAR FOR THE BUSINESS Key growth drivers for FY27/ beyond 1 • EU-CDMO book of business ramping up • With a third injectable • Rs.100+ cr. at the end of Q1 unit set to be • Rs. 700-800 cr. at the end of Q2 commissioned in FY28 • Rs. 1,000+ cr. at the end
Slide 16: Consolidated
• Domestic Branded Formulations • International Business • Consolidated 15
Slide 17: Consolidated Operating Financials – Highest Ever Quarterly Revenue
CONSOLIDATED OPERATING FINANCIALS – HIGHEST EVER QUARTERLY REVENUE Consolidated Revenue (Rs. Cr.) Consolidated Revenue – Q3 and 9M 8.4% 11% 2,188 2,373 • Q3 Revenue = Rs. 807 cr. (up 11% yoy) 727 807 • 9M Revenue = Rs. 2,373 cr. (up 8.4% yoy) Q3 FY25 Q3 FY26 9M FY25 9M FY26 Consolidated Revenue ex.
Slide 18: Consolidated Operating Financials – Operating Profit
CONSOLIDATED OPERATING FINANCIALS – OPERATING PROFIT Consolidated EBIDTA (%) 11% 847 • Q3 EBIDTA = Rs. 282 cr. (up 13% yoy) 13% 765 Consol. FY26 visibility • Q3 Margin = 35% (up 62 bps) 250 282 Revenue ~ Rs. 3,200 cr. • 9M EBIDTA = Rs. 847 cr. (up 11% yoy) • 10% yoy growth Q3 FY25 Q3 FY26 9M FY25 9M
Slide 19: Consolidated Profit After Tax – Q3 and 9M FY26
CONSOLIDATED PROFIT AFTER TAX – Q3 AND 9M FY26 Consolidated PAT (Rs. Cr.) – Q3 FY26 38.5% 120 Consolidated PAT – Key Drivers 109 87 • Reduction in interest expenses • 15% in Q3 FY26 Adjusted for • 17% over 9M FY26 Q3 FY25 Q3 FY26 Q3 FY26 an exceptional • 207 bps reduction in 9M book tax rate item (R
Slide 20: Debt Reduction – Reiterating Guidance of <1.5x Debt-to-EBIDTA by Dec-26
DEBT REDUCTION – REITERATING GUIDANCE OF < 1.5x DEBT-TO-EBIDTA BY DEC-26 Debt-to-EBIDTA Ratio Debt-to-EBIDTA Ratio Debt Reduction guidance Plan shared at the start of FY26 Outlook at the end of Q2-FY26 • Net Debt to TTM EBIDTA ratio has significantly Outstanding Debt to Outstanding Debt to As On Dat
Slide 21: Consolidated P&L Statement – Q3 and 9M FY26
CONSOLIDATED P&L STATEMENT – Q3 AND 9M FY26 YoY YoY Consolidated (Rs. Cr) Q3 FY 26 Q3 FY 25 9M FY 26 9M FY 25 (%) (%) Consolidated Highlights – Q3 and 9M Revenue from Operations 807 727 11.0% 2,373 2,188 8.4% Gross Profit 584 551 6.1% 1,763 1,645 7.2% • YoY reduction in depreciation, finance Gross M
Slide 22: Shareholder Profile
SHAREHOLDER PROFILE Shareholding of Promoters and Top 15 Institutional Investors Shareholding Pattern as of Dec 2025 31-Dec-25 30-Sept-25 30-Jun-25 Name of Shareholder Others, 1,506* 1,586* 1,684* Public, 8.51% 0.69% Promoters 54.85% 54.87% 54.83% FPIs, 15.64% Lilac Investments Ltd. 8.78% 8.78% 8.79
Slide 23: Safe Harbor Statement
SAFE HARBOR STATEMENT This presentation contains forward-looking statements and information that involve risks, uncertainties and assumptions. Forward-looking statements are all statements that concern plans, objectives, goals, strategies, future events or performance and the underlying assumptions
Slide 24: Thank You!
Registered Office Shivarth Ambit, Plot No 142/2, Ramdas Road Off SBR, Near Swati Bungalows, Bodakdev, Ahmedabad, Gujarat - 380054 For Further Information, Please Contact: Thank You! Kruti Raval / Atul Modi https://eris.co.in/ investor.relations@eris.co.in E: kruti@erislifesciences.com E: atul.modi@e
Eris Lifesciences — Q3 and 9M FY26 Earnings Presentation on 6ix